Biotech Values

[mcbio]

After a few day of waffling between MNTA, NKTR and AMRN, I just pulled the trigger on AMRN. Love the 26% insider ownership and the 26% increase of institutional holdings last qtr. The market is massive and we shall see. Thanks for your input.

No way I would have picked AMRN over MNTA but good luck to you and hope things work out for you. With MNTA, you already have a big-selling drug approved and bringing in nice cash plus several other ways to win in generic Copaxone, FOBs, M118, etc. With AMRN, if you don't get positive ANCHOR results, you face the likelihood of being in the hole (possibly in a big way).